Peter Svalander

Corporate Officer/Principal presso University of Gothenburg

Commercial Services

Consumer Services

Profilo

Peter Svalander is a Professor at the University of Gothenburg.
Prior to this, he worked as a Director at Avaris AB and as President at Swedish Biotechnology AB.

Posizioni attive di Peter Svalander

Società	Posizione	Inizio
University of Gothenburg	Corporate Officer/Principal	02/06/2010

Tutte le posizioni attive di Peter Svalander

Precedenti posizioni note di Peter Svalander

Società	Posizione	Fine
Swedish Biotechnology AB	Presidente	-
Avaris AB Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Peter Svalander

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Peter Svalander

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Avaris AB Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.	Commercial Services
Swedish Biotechnology AB